Related Experiment Video
Updated: Aug 24, 2025
Fabrication of Electrochemical-DNA Biosensors for the Reagentless Detection of Nucleic Acids, Proteins and Small Molecules
Published on: June 1, 2011
Electrochemical biosensors for analysis of DNA point mutations in cancer research
Katerina Ondraskova1,2, Ravery Sebuyoya1,2, Ludmila Moranova1
1Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic.
Abstract:
Cancer is a genetic disease induced by mutations in DNA, in particular point mutations in important driver genes that lead to protein malfunctioning and ultimately to tumorigenesis. Screening for the most common DNA point mutations, especially in such genes as TP53, BRCA1 and BRCA2, EGFR, KRAS, or BRAF, is crucial to determine predisposition risk for cancer or to predict response to therapy. In this review, we briefly depict how these genes are involved in cancer, followed by a description of the most common techniques routinely applied for their analysis, including high-throughput next-generation sequencing technology and less expensive low-throughput options, such as real-time PCR, restriction fragment length polymorphism, or high resolution melting analysis. We then introduce benefits of electrochemical biosensors as interesting alternatives to the standard methods in terms of cost, speed, and simplicity. We describe most common strategies involved in electrochemical biosensing of point mutations, relying mostly on PCR or isothermal amplification techniques, and critically discuss major challenges and obstacles that, until now, prevented their more widespread application in clinical settings.
Insights
Detecting critical DNA point mutations in cancer genes like TP53 and BRCA is vital for risk assessment and treatment prediction. Electrochemical biosensors offer a promising, cost-effective alternative to current methods for mutation analysis.
Area of Science:
- Oncology
- Genetics
- Biotechnology
Background:
- Cancer arises from DNA mutations, particularly point mutations in key driver genes, leading to protein dysfunction and tumor development.
- Identifying mutations in genes such as TP53, BRCA1/BRCA2, EGFR, KRAS, and BRAF is essential for cancer risk stratification and predicting therapeutic responses.
Purpose of the Study:
- To review the role of specific genes in cancer development.
- To describe current methods for analyzing cancer-associated DNA point mutations.
- To introduce electrochemical biosensors as a novel, advantageous alternative for mutation detection.
Main Methods:
- Review of literature on cancer genetics and mutation detection techniques.
- Description of established methods: next-generation sequencing (NGS), real-time PCR, restriction fragment length polymorphism (RFLP), and high-resolution melting analysis (HRMA).
- Exploration of electrochemical biosensor strategies, often coupled with PCR or isothermal amplification.
Main Results:
- Standard methods for DNA point mutation analysis include high-throughput NGS and lower-throughput techniques like PCR and HRMA.
- Electrochemical biosensors present significant advantages in terms of cost, speed, and simplicity for detecting point mutations.
- Current challenges hinder the widespread clinical adoption of electrochemical biosensors for mutation analysis.
Conclusions:
- Accurate detection of DNA point mutations in critical cancer genes is fundamental for personalized medicine.
- Electrochemical biosensors show potential to revolutionize cancer mutation screening by offering efficient and accessible diagnostic tools.
- Overcoming existing technical and implementation hurdles is necessary for integrating biosensors into routine clinical practice.
